At the time of writing this article, I checked BioDelivery International Inc. (BDSI) website and its latest SEC filings for any news related to the fact that Reckitt Benckiser Pharmaceuticals (RBP) has sued BDSI for filing a New Drug Application for BUNAVAIL, a lead product in BDSI's pipeline. I am surprised why BDSI has not informed their investors regarding this material event. With this new litigation, BDSI shares may put off some of the gains that were priced in over past several months in anticipation of a timely approval and/or securing a partner for BUNAVAIL.
About RBP: It's a part of ~$46B Reckitt Benckiser Group Plc (OTC:RBGPY), a manufacturer and marketer of branded...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: